JGUA
UTHR icon

John G. Ullman & Associates’s United Therapeutics UTHR Stock Holding History

John G. Ullman & Associates’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.77M Sell
6,355
-600
-9% -$299K 0.5% 63
2025
Q4 		$3.39M Sell
6,955
-125
-2% -$58.2K 0.45% 68
2025
Q3 		$2.97M Sell
7,080
-201
-3% -$67.6K 0.4% 69
2025
Q2 		$2.09M Sell
7,281
-75
-1% -$22.4K 0.31% 81
2025
Q1 		$2.27M Buy
7,356
+1
+0% +$343 0.35% 83
2024
Q4 		$2.6M Sell
7,355
-80
-1% -$29.4K 0.38% 76
2024
Q3 		$2.66M Sell
7,435
-15
-0.2% -$5.07K 0.38% 75
2024
Q2 		$2.37M Sell
7,450
-300
-4% -$79.4K 0.36% 80
2024
Q1 		$1.78M Sell
7,750
-1,380
-15% -$311K 0.27% 81
2023
Q4 		$2.01M Sell
9,130
-100
-1% -$23K 0.32% 82
2023
Q3 		$2.08M Sell
9,230
-125
-1% -$28.8K 0.34% 81
2023
Q2 		$2.07M Buy
9,355
+930
+11% +$206K 0.32% 83
2023
Q1 		$1.89M Buy
+8,425
New +$2.08M 0.29% 78

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

John G. Ullman & Associates's UTHR Position: Q1 2026 in Review

John G. Ullman & Associates reduced its United Therapeutics (UTHR) stake by 8.6% in Q1 2026, selling an estimated $299K and leaving 6,355 shares worth $3.77M. The position accounts for 0.5% of the portfolio, ranked #63.

John G. Ullman & Associates first reported a position in UTHR in Q1 2023 and has held it in 13 quarters since. 850 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

  • John G. Ullman & Associates held 6,355 shares of United Therapeutics worth $3.77M as of Q1 2026.
  • John G. Ullman & Associates sold 600 United Therapeutics shares in Q1 2026, an estimated $299K.
  • United Therapeutics made up 0.5% of John G. Ullman & Associates's portfolio in Q1 2026, its #63 holding.
  • John G. Ullman & Associates first reported a position in United Therapeutics in Q1 2023 and has held it in 13 quarters since.
  • 850 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on John G. Ullman & Associates's 13F filing for Q1 2026, filed 6 May 2026.